Evidence map›Paper›PMID 37600803›Full record

ArticleFrontiers in immunology2023

Crosstalk between hypoxic cellular micro-environment and the immune system: a potential therapeutic target for infectious diseases.

Olalekan Chris Akinsulie, Sammuel Shahzad, Seto Charles Ogunleye, Ifeoluwa Peace Oladapo, Melina Joshi, Charles Egede Ugwu, Joy Olaoluwa Gbadegoye, Fasilat Oluwakemi Hassan, Richard Adeleke, Qudus Afolabi Akande and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Hypoxia-responsive geneJournal of Cancer · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Olalekan Chris AkinsulieDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.
Sammuel ShahzadDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.
Seto Charles OgunleyeCollege of Veterinary Medicine, Mississippi State University, Starkville, MS, United States.
Ifeoluwa Peace OladapoDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, United States.
Melina JoshiCenter for Molecular Dynamics Nepal, Kathmandu, Nepal.
Charles Egede UgwuPaul G. Allen School for Global Health, Washington State University, Pullman, WA, United States.
Joy Olaoluwa GbadegoyeDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN, United States.
Fasilat Oluwakemi HassanDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN, United States.
Richard AdelekeCollege of Veterinary Medicine, Cornell University, Ithaca, NY, United States.
Qudus Afolabi AkandeDepartment of Biological Sciences, University of Notre Dame, Notre Dame, IN, United States.
Ridwan Olamilekan AdesolaFaculty of Veterinary Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
Washington State University · USUniversity of Tennessee Health Science Center · USCenter for Molecular Dynamics - Nepal · NPMississippi State University · USNew York State College of Veterinary Medicine · USUniversity of Ibadan · NGUniversity of Notre Dame · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are overwhelming reports on the promotional effect of hypoxia on the malignant behavior of various forms of cancer cells. This has been proposed and tested exhaustively in the light of cancer immunotherapy. However, there could be more interesting functions of a hypoxic cellular micro-environment than malignancy. There is a highly intricate crosstalk between hypoxia inducible factor (HIF), a transcriptional factor produced during hypoxia, and nuclear factor kappa B (NF-κB) which has been well characterized in various immune cell types. This important crosstalk shares common activating and inhibitory stimuli, regulators, and molecular targets. Impaired hydroxylase activity contributes to the activation of HIFs. Inflammatory ligands activate NF-κB activity, which leads to the expression of inflammatory and anti-apoptotic genes. The eventual sequelae of the interaction between these two molecular players in immune cells, either bolstering or abrogating functions, is largely cell-type dependent. Importantly, this holds promise for interesting therapeutic interventions against several infectious diseases, as some HIF agonists have helped prevent immune-related diseases. Hypoxia and inflammation are common features of infectious diseases. Here, we highlighted the role of this crosstalk in the light of functional immunity against infection and inflammation, with special focus on various innate and adaptive immune cells. Particularly, we discussed the bidirectional effects of this crosstalk in the regulation of immune responses by monocytes/macrophages, dendritic cells, neutrophils, B cells, and T cells. We believe an advanced understanding of the interplay between HIFs and NF-kB could reveal novel therapeutic targets for various infectious diseases with limited treatment options.

Indexed as

Communicable DiseasesNF-kappa BHumansHypoxiaImmunotherapyLeukocytesNF-kappa BHIFshypoxiaimmune cellsinfectious diseasesinflammationNF-kB

Identifiers

PMID37600803
PMCPMC10434535
OpenAlexW4385480935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.